ATE319452T1 - Arzneimittel gegen essstörungen - Google Patents
Arzneimittel gegen essstörungenInfo
- Publication number
- ATE319452T1 ATE319452T1 AT00970169T AT00970169T ATE319452T1 AT E319452 T1 ATE319452 T1 AT E319452T1 AT 00970169 T AT00970169 T AT 00970169T AT 00970169 T AT00970169 T AT 00970169T AT E319452 T1 ATE319452 T1 AT E319452T1
- Authority
- AT
- Austria
- Prior art keywords
- eating disorders
- medicines
- independently represent
- chem
- pharmaceutically acceptable
- Prior art date
Links
- 208000030814 Eating disease Diseases 0.000 title abstract 2
- 208000019454 Feeding and Eating disease Diseases 0.000 title abstract 2
- 235000014632 disordered eating Nutrition 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31013899 | 1999-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE319452T1 true ATE319452T1 (de) | 2006-03-15 |
Family
ID=18001632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00970169T ATE319452T1 (de) | 1999-10-29 | 2000-10-27 | Arzneimittel gegen essstörungen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050176739A1 (de) |
| EP (1) | EP1234576B1 (de) |
| AT (1) | ATE319452T1 (de) |
| AU (1) | AU7962000A (de) |
| CA (1) | CA2388176C (de) |
| DE (1) | DE60026559T2 (de) |
| ES (1) | ES2260061T3 (de) |
| WO (1) | WO2001032182A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1658291T3 (da) * | 2003-08-25 | 2013-10-28 | Dogwood Pharmaceuticals Inc | Substituerede 8-heteroaryl xanthiner |
| TWI346114B (en) * | 2003-09-29 | 2011-08-01 | Method for stabilization of diarylvinylene compounds | |
| EP4118083A4 (de) | 2020-03-10 | 2024-07-03 | Marvel Biotechnology | Purinverbindungen zur behandlung von erkrankungen |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2729642A (en) * | 1954-08-13 | 1956-01-03 | Chattanooga Medicine Co | Water soluble salts of 8-(para-aminobenzyl) caffeine and method for their preparation |
| US3641010A (en) * | 1970-06-11 | 1972-02-08 | Parke Davis & Co | Novel xanthine compounds and means for obtaining the same |
| US4593095A (en) * | 1983-02-18 | 1986-06-03 | The Johns Hopkins University | Xanthine derivatives |
| EP0559893B1 (de) * | 1990-10-18 | 1999-02-03 | Kyowa Hakko Kogyo Co., Ltd. | Xanthinderivate |
| JP2928386B2 (ja) * | 1992-07-08 | 1999-08-03 | 協和醗酵工業株式会社 | うつ病治療剤 |
| JP2613355B2 (ja) * | 1992-09-28 | 1997-05-28 | 協和醗酵工業株式会社 | パーキンソン氏病治療剤 |
| CA2112031A1 (en) * | 1992-12-24 | 1994-06-25 | Fumio Suzuki | Xanthine derivatives |
| TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| US6489341B1 (en) * | 1999-06-02 | 2002-12-03 | Sepracor Inc. | Methods for the treatment of neuroleptic and related disorders using sertindole derivatives |
-
2000
- 2000-10-27 AT AT00970169T patent/ATE319452T1/de not_active IP Right Cessation
- 2000-10-27 WO PCT/JP2000/007586 patent/WO2001032182A1/ja not_active Ceased
- 2000-10-27 AU AU79620/00A patent/AU7962000A/en not_active Abandoned
- 2000-10-27 EP EP00970169A patent/EP1234576B1/de not_active Expired - Lifetime
- 2000-10-27 DE DE60026559T patent/DE60026559T2/de not_active Expired - Fee Related
- 2000-10-27 CA CA002388176A patent/CA2388176C/en not_active Expired - Fee Related
- 2000-10-27 ES ES00970169T patent/ES2260061T3/es not_active Expired - Lifetime
-
2005
- 2005-04-13 US US11/104,623 patent/US20050176739A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1234576A4 (de) | 2004-03-31 |
| DE60026559D1 (de) | 2006-05-04 |
| ES2260061T3 (es) | 2006-11-01 |
| CA2388176C (en) | 2007-09-25 |
| CA2388176A1 (en) | 2001-05-10 |
| DE60026559T2 (de) | 2006-12-14 |
| EP1234576A1 (de) | 2002-08-28 |
| WO2001032182A1 (en) | 2001-05-10 |
| AU7962000A (en) | 2001-05-14 |
| US20050176739A1 (en) | 2005-08-11 |
| EP1234576B1 (de) | 2006-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69528005D1 (de) | Prolineamid-Derivate | |
| WO2002085909A8 (en) | 9-deazaguanine derivatives as inhibitors of gsk-3 | |
| AR023957A1 (es) | Pirazol carboxamidas utiles para el tratamiento de la obesidad y otros trastornos. | |
| DE60023878D1 (de) | Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen | |
| CA2311742A1 (en) | 6-amino-9-benzyl-8-hydroxypurine derivatives | |
| GEP20074208B (en) | Substituted amides active at the cannabinoid-1 receptor | |
| DK0734383T3 (da) | Cykliske amidderivater som neurokinin-A-antagonister | |
| EP1201239A4 (de) | Cyclische amine als ccr3 antagonisten | |
| CY1112899T1 (el) | Παραγωγα θειαδιαζολινης για τη θεραπεια του καρκινου | |
| DE69834500D1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
| GR3025568T3 (en) | Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia. | |
| DE69931378D1 (de) | Chinazolin derivate und therapeutische verwendungen davon | |
| EP1034783A4 (de) | Amidederivaten | |
| ATE319452T1 (de) | Arzneimittel gegen essstörungen | |
| DK0896822T3 (da) | 4-aminopyrrol (3,2-d) pyrimidiner som neuropeptide Y receptorantagonister | |
| EP1062948A4 (de) | Arzneimittel für diastolische herzerkrankungen | |
| WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
| DE69635775D1 (de) | Medikament gegen pulmonale herzprobleme | |
| PT855398E (pt) | Derivados sasquiterpeno tendo actividade antiviral | |
| DE60238847D1 (de) | Pyrimidinderivate enthaltendes medikament | |
| EP1466909A4 (de) | Halogenbenzylaminopropionsäurederivate | |
| EP1650191A4 (de) | Therapeutisches mittel gegen chronische obstruktive atemwegserkrankung und verfahren zur behandlung von chronisch obstruktiver atemwegserkrankung mit diesem mittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1234576 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |